0UI8 Stock Overview
A clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aptose Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.33 |
| 52 Week High | CA$6.87 |
| 52 Week Low | CA$1.33 |
| Beta | 1.47 |
| 11 Month Change | -14.19% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0UI8 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -1.4% |
| 1Y | n/a | -25.7% | 6.3% |
Return vs Industry: Insufficient data to determine how 0UI8 performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0UI8 performed against the UK Market.
Price Volatility
| 0UI8 volatility | |
|---|---|
| 0UI8 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0UI8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0UI8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 36 | William Rice | www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.
Aptose Biosciences Inc. Fundamentals Summary
| 0UI8 fundamental statistics | |
|---|---|
| Market cap | CA$22.40m |
| Earnings (TTM) | -CA$64.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs 0UI8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0UI8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.17m |
| Earnings | -US$47.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0UI8 perform over the long term?
See historical performance and comparison